Hyperthermic intraperitoneal chemotherapy as consolidation treatment of advanced stage ovarian cancer
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
ObjectiveTo investigate the therapeutic efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) as consolidationtreatment after completing first-line treatment in patients with advanced ovarian cancer. MethodsA retrospective chart review was conducted on patients treated at the Comprehensive Gynecologic Cancer Centerbetween January 2014 and 2019. Based on the inclusion criteria, 24 eligible patients who received HIPEC (paclitaxel175 mg/m2, for 90 minutes, at 42°C) (HIPEC group) as consolidation treatment after terminating the adjuvantchemotherapy were identified. Another 24 patients who met the inclusion criteria and did not receive HIPEC werematched, representing the non-HIPEC group. Disease-free survival (DFS) and overall survival (OS) were examinedbetween the two groups. ResultsThe median DFS was 28.7 and 24.2 months in the HIPEC and non-HIPEC groups, respectively (P=0.688). The 3-yearDFS rates in the HIPEC and non-HPEC groups were 39.5% and 32.6%, respectively. However, the median OS was notdetermined. The 5-year OS rates in the HIPEC and non-HIPEC groups were 86.2% and 81.3%, respectively (P=0.850). One patient developed grade 3 neutropenia. Other patients experienced mild adverse events after HIPEC. ConclusionThis study suggests that consolidation HIPEC could not support the survival benefit after completing the first-linetreatment for patients with advanced ovarian cancer, although no severe specific safety issues were found. Therefore,randomized trials evaluating consolidation HIPEC for the management of ovarian cancer are warranted.
Abstract
ObjectiveTo investigate the therapeutic efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) as consolidationtreatment after completing first-line treatment in patients with advanced ovarian cancer. MethodsA retrospective chart review was conducted on patients treated at the Comprehensive Gynecologic Cancer Centerbetween January 2014 and 2019. Based on the inclusion criteria, 24 eligible patients who received HIPEC (paclitaxel175 mg/m2, for 90 minutes, at 42°C) (HIPEC group) as consolidation treatment after terminating the adjuvantchemotherapy were identified. Another 24 patients who met the inclusion criteria and did not receive HIPEC werematched, representing the non-HIPEC group. Disease-free survival (DFS) and overall survival (OS) were examinedbetween the two groups. ResultsThe median DFS was 28.7 and 24.2 months in the HIPEC and non-HIPEC groups, respectively (P=0.688). The 3-yearDFS rates in the HIPEC and non-HPEC groups were 39.5% and 32.6%, respectively. However, the median OS was notdetermined. The 5-year OS rates in the HIPEC and non-HIPEC groups were 86.2% and 81.3%, respectively (P=0.850). One patient developed grade 3 neutropenia. Other patients experienced mild adverse events after HIPEC. ConclusionThis study suggests that consolidation HIPEC could not support the survival benefit after completing the first-linetreatment for patients with advanced ovarian cancer, although no severe specific safety issues were found. Therefore,randomized trials evaluating consolidation HIPEC for the management of ovarian cancer are warranted.
참고문헌 (23)
- Carlson KJ, "Screening for ovarian cancer", Ann Intern Med, 121, pp.124~132 (1994)
- du Bois A, "Role of neoadjuvant chemotherapy in advanced epithelial ovarian cancer", J Clin Oncol, 37, pp.2398~2405 (2019)
- Cannistra SA, "Cancer of the ovary", N Engl J Med, 351, pp.2519~2529 (2004)
- Armstrong DK, "Intraperitoneal cisplatin and paclitaxel in ovarian cancer", N Engl J Med, 354, pp.34~43 (2006)
- Jaaback K, "Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer", Cochrane Database Syst Rev, (1), pp.CD005340~ (2016)
- Bakrin N, "Hyperthermic intraperitoneal chemotherapy(HIPEC)in ovarian cancer", J Visc Surg, 151, pp.347~353 (2014)
- Ohno S, "Thermal enhancement of drug uptake and DNA adducts as a possible mechanism for the effect of sequencing hyperthermia on cisplatin-induced cytotoxicity in L1210 cells", Cancer Chemother Pharmacol, 34, pp.302~306 (1994)
- van de Vaart PJ, "Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer : pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines", Eur J Cancer, 34, pp.148~154 (1998)
- van Driel WJ, "Hyperthermic intraperitoneal chemotherapy in ovarian cancer", N Engl J Med, 378, pp.230~240 (2018)
- Choi MC, "Germline mutations of BRCA1 and BRCA2 in Korean ovarian cancer patients : finding founder mutations", Int J Gynecol Cancer, 25, pp.1386~1391 (2015)
- Hess LM, "A meta-analysis of the efficacy of intraperitoneal cisplatin for the frontline treatment of ovarian cancer", Int J Gynecol Cancer, 17, pp.561~570 (2007)
- Walker JL, "Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma : an NRG Oncology", Gynecologic Oncology Group Study, 2019, pp.37, 1380~1390
- Mulier S, "Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy(HIPEC)at the different time-points of treatment of ovarian cancer : review of evidence", Curr Pharm Des, 18, pp.3793~3803 (2012)
- Spiliotis J, "Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer : a prospective randomized phase III study", Ann Surg Oncol, 22, pp.1570~1575 (2015)
- Bae JH, "Treatment of ovarian cancer with paclitaxel-or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery", Gynecol Oncol, 106, pp.193~200 (2007)
- Mendivil AA, "Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma : a 3 year experience", Cancer Chemother Pharmacol, 80, pp.405~410 (2017)
- Gori J, "Intraperitoneal hyperthermic chemotherapy in ovarian cancer", Int J Gynecol Cancer, 15, pp.233~239 (2005)
- Nayl B, "Six versus nine cycles of paclitaxel-carboplatin as first-line chemotherapy in patients with newly diagnosed epithelial advanced ovarian cancer", J Clin Oncol, 27(15_suppl), pp.e16535~ (2009)
- Tewari KS, "Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer", J Clin Oncol, 37, pp.2317~2328 (2019)
- Mirza MR, "The forefront of ovarian cancer therapy : update on PARP inhibitors", Ann Oncol, 31, pp.1148~1159 (2020)
- Huang YW, "Association of BRCA1", 2 mutations with ovarian cancer prognosis: an updated meta-analysis, 2018, pp.97, e9380~
- Cowan RA, "Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy(HIPEC)clinical trials in ovarian cancer", Int J Hyperthermia, 33, pp.548~553 (2017)
- Riggs MJ, "Hyperthermic intraperitoneal chemotherapy in ovarian cancer", Diagnostics(Basel), 10, pp.43~ (2020)